Pulse nav.journalClub Tendencias Explorar Preguntas Investigadores

Download the App

Join discussions, follow papers, and never miss your next session.

© Synapse Social LLC, 2026Política de privacidad

⌘+K

State Coverage and Reimbursement of Antiobesity Medications in Medicaid | Synapse

March 14, 2024Open Access

State Coverage and Reimbursement of Antiobesity Medications in Medicaid

Leer artículo completoexternamente

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

This study examines state Medicaid coverage policies for antiobesity medications and their trends in Medicaid reimbursement from 2011 to 2022.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Loading...

Cite this study

Liu et al. (Thu,) studied this question.

synapsesocial.com/papers/68e73fdcb6db6435876b95cb — DOI: https://doi.org/10.1001/jama.2024.3073

Authors

B

Benjamin Y. Liu

Cornell University

B

Benjamin N. Rome

Boston University

Journals

JAMA

Actions

Institutions

Brigham and Women's Hospital

Beth Israel Deaconess Medical Center

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Loading...

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Spending, utilization, and price trends for anti-obesity medications in U.S. Medicaid programs: an empirical analysis from 1999 to 2023· 2025 · 2 citations
Navigating coverage: A qualitative study exploring the perceived impact of an insurance company policy to discontinue coverage of antiobesity medication· 2024 · 6 citations
Coverage for Opioid Use Disorder Medications in Medicaid Managed Care· 2025 · 2 citations
The Benefits and Costs of Treating Obesity Among Adults in the Medicaid Program· 2026
Survey-Reported Coverage in 2019-2022 and Implications for Unwinding Medicaid Continuous Eligibility· 2024 · 28 citations